CompletedNCT04979910
Ixekizumab study for people with treatment-resistant depression
About this title
Read the official source — NCT04979910Medication studyAges 18–70United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 27, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 7
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT04979910
- Official title
Show the full official title
An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Did this study involve medication?
Yes. The study involved medication, including Ixekizumab.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
